Mustbio revealed preclinical study results of its lead compound, MB5029, aPD-1 x IL-2v bispecific fusion protein, at the 2024 Association for Cancer Research Annual Meeting (AACR). The results highlighted the drug's potent anti-tumor efficacy and improved safety profile. 

Highlights: 

● MB5029 is an innovative anti-PD-1 and IL-2v bispecific fusion protein with a unique non-α and γ-attenuated IL-2v. 

● MB5029 demonstrates TME selective immune cell activation and minimal effects in PB, resulting in strong anti-tumor efficacy and robust safety profiles in various animal models. 

● Preclinical observations support that MB5029 holds the potential to provide a best-in-class therapeutic option to cancer patients.